{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.1","upperLimit":"73.7","value":"58.5"}]}],"title":"Up to approx. 3.2 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.5","upperLimit":"75.8","value":"61.0"}]}],"title":"Up to approx. 4.8 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"ORR in the HGG cohort defined as the percentage of participants in the HGG cohort with a best overall confirmed CR or PR as assessed per RANO criteria by investigator assessment. The 95% CIs were computed using two-sided exact binomial method.\n\nCR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.\n\nPR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"}],"paramType":"NUMBER","populationDescription":"All participants on the HGG cohort to whom study treatment had been assigned and who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approx. 3.2 years and up to approx. 4.8 years","title":"HGG Cohort: ORR by Investigator Assessment Using RANO Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}